# Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

> **NCT00588822** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 21 (actual)

## Conditions studied

- Precancerous Condition

## Interventions

- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT00588822
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2009-01
- **Final completion:** 2011-02
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Discontinuation due to the high response rate at the 1st stage and slow accrual.
- **Last updated:** 2014-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00588822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00588822, "Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00588822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*